Please ensure Javascript is enabled for purposes of website accessibility

Bristol-Myers Squibb's Earnings Get a Boost From Celgene Acquisition

By Brian Orelli, PhD – Updated Feb 6, 2020 at 12:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmaceutical giant's guidance also looks good.

Fourth-quarter revenue at Bristol-Myers Squibb (BMY -0.53%) jumped 33% year over year thanks to its purchase of Celgene, which closed in the latter half of November. On a generally accepted accounting principles (GAAP) basis, the company lost $0.55 per share due to the aforementioned acquisition. But on an adjusted basis, earnings were up 30% year over year to $1.22 per share. The results sent shares of Bristol-Myers higher. The stock was trading up 2% at 11:16 a.m. EST.

Sales of its top-selling drug Eliquis, which treats blood clots, jumped 19% year over year. Cancer treatment Opdivo is still a major blockbuster with revenues topping $1.7 billion in the quarter, but its sales were down 2% year over year due to competition from Merck's Keytruda and other drugs attacking the same immunotherapy mechanism.

Doctor with her hand on a patient's shoulder

Image source: Getty Images.

The big pharma plans to pay down debt to help maintain its credit rating, but noted that it still plans to increase its dividend and do additional deals -- licensing or acquisitions -- as well as repurchase shares. The board authorized an additional $5 billion for stock buybacks in addition to the approximately $1 billion that it had remaining under a 2016 authorization.

For this year, management expects revenue of $40.5 billion to $42.5 billion. On a GAAP basis, earnings per share are forecast to land in the $0.75 to $0.95 range as the Celgene acquisition continues to put a drag on earnings. On an adjusted basis, earnings per share are expected to be in the $6.00 to $6.20 range, up 30% at the midpoint. Management also gave adjusted earnings per share guidance for 2021, when it thinks the company will bring in $7.15 to $7.45, up almost 20% at the midpoint for guidance in both years.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol-Myers Squibb. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Stock Quote
Bristol Myers Squibb
$70.53 (-0.53%) $0.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.